Get the Stockscreener App
0.687
17.72%
-0.148
After Hours:
.72
0.033
+4.80%
Eterna Therapeutics Inc stock is traded at $0.687, with a volume of 444.10K.
It is down -17.72% in the last 24 hours and down -32.65% over the past month.
Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.
See More
Previous Close:
$0.835
Open:
$0.7311
24h Volume:
444.10K
Relative Volume:
8.69
Market Cap:
$37.36M
Revenue:
-
Net Income/Loss:
$-21.67M
P/E Ratio:
-0.1218
EPS:
-5.64
Net Cash Flow:
$-20.41M
1W Performance:
-39.20%
1M Performance:
-32.65%
6M Performance:
-65.65%
1Y Performance:
-39.20%
1-Day Range:
$0.65
$0.7451
1-Week Range:
$0.65
$1.20
52-Week Range:
$0.65
$2.625
Eterna Therapeutics Inc Stock (ERNA) Company Profile
Name
Eterna Therapeutics Inc
Sector
Industry
Phone
(212) 582-1199
Address
1035 CAMBRIDGE STREET, CAMBRIDGE
Compare ERNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ERNA | 0.687 | 37.36M | 0 | -21.67M | -20.41M | -5.64 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Eterna Therapeutics Inc Stock (ERNA) Latest News
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com - Defense World
ERNA Stock Hits 52-Week Low at $0.83 Amid Market Challenges - Investing.com India
Eterna Therapeutics regains Nasdaq compliance, focuses on cancer therapy - Investing.com
Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing - The Manila Times
Eterna Therapeutics Regains Nasdaq Compliance, Advances Cancer Treatment Pipeline | ERNA Stock News - StockTitan
Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com - MarketBeat
Eterna Therapeutics shareholder Charles Cherington sells $6.54m in stock - Investing.com
Eterna Therapeutics shareholder Charles Cherington sells $6.54m in stock By Investing.com - Investing.com UK
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success - GlobeNewswire
Eterna Therapeutics announces share issuance and executive agreements By Investing.com - Investing.com South Africa
Eterna Therapeutics announces share issuance and executive agreements - Investing.com India
Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
Eterna, Factor announce license, collaboration agreement - Yahoo Finance
Factor Bioscience and Eterna Therapeutics Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases - BioSpace
Eterna secures exclusive license for cell therapy tech - Investing.com India
Eterna secures exclusive license for cell therapy tech By Investing.com - Investing.com UK
Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases - GlobeNewswire
Eterna Therapeutics : Presentation (ZwKlOLVsGrYSwatS Zv 5rrVsGrYSwY0B EternaTherapeutics FactSheet October03%2C2024Final v1) - Marketscreener.com
Eterna Therapeutics Inc. (NASDAQ:ERNA) Sees Large Growth in Short Interest - Defense World
Eterna Therapeutics inks new license agreement, ends previous Factor Bioscience deals - Investing.com
Eterna Therapeutics Strikes Key Deal for Disease-Fighting Tech - TipRanks
Eterna Therapeutics Inc: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Eterna Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada
Eterna Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com
Eterna Therapeutics Inc. announced that it expects to receive $5.037748 million in funding - Marketscreener.com
Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com - MarketBeat
StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World
Eterna Therapeutics (NASDAQ:ERNA) Shares Up 2.4% - Defense World
Eterna Therapeutics sets September 27 for annual meeting By Investing.com - Investing.com Australia
Eterna Therapeutics sets September 27 for annual meeting - Investing.com
ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q2 2024 - MSN
Eterna Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board - GlobeNewswire
Eterna Therapeutics Inc. (NASDAQ:ERNA) Short Interest Update - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Receives New Coverage from Analysts at StockNews.com - Defense World
Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics - Quantisnow
Brooklyn ImmunoTherapeutics to Participate in Grand Opening of Cambridge-Based mRNA Cleanroom Facility Shared ... - Quantisnow
Brooklyn ImmunoTherapeutics Set to Join Russell 3000 Index - Quantisnow
Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing - Quantisnow
Brooklyn ImmunoTherapeutics Reports Inducement Grants - Quantisnow
Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private Placement - Quantisnow
StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World
Eterna Therapeutics Inc Stock (ERNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.66%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):